8-K
filed December 29, 2023, 6:59 PM ET
ticker NRXP
CIK 0001719406
other material
confidence high
sentiment neutral
materiality 0.40
NRx Pharmaceuticals shareholders approve share increase, elect director at 2023 annual meeting
NRX Pharmaceuticals, Inc.
- Elected Janet Rehnquist as Class II director: 43.7M votes for, 0.5M withheld.
- Approved amendment to 2021 Omnibus Plan: share pool raised from 6,713,608 to 8,713,608 shares; 29.7M for, 13.5M against.
- Ratified Salberg & Company as independent auditor for FY2023: 42.1M for, 1.9M against.
- Advisory 'say-on-pay' approved (32.0M for, 11.4M against); board set future advisory votes on exec compensation to annual.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.7
NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.
- Proposal
- say on pay frequency
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on executive compensation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.
- Proposal
- say on pay
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NRX Pharmaceuticals, Inc. shareholders approved Approval of the Plan Amendment.
- Outcome
- passed
Exact text from the filing
The Company’s stockholders approved the Plan Amendment.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NRX Pharmaceuticals, Inc. shareholders approved Ratification of Salberg & Company, P.A. as independent auditors for fiscal year 2023 at the 2023-12-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-12-31
Exact text from the filing
The Company’s stockholders ratified the selection of Salberg & Company, P.A. as the Company’s independent auditors for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
NRX Pharmaceuticals, Inc. shareholders approved Election of Janet Rehnquist as a Class II director.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The Company’s stockholders duly elected Janet Rehnquist to serve as a Class II member of the Company’s board of directors until the 2026 Annual Meeting or until the appointment, election, and qualification of her successor.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.